Wegovy® (semaglutide) – Expanded indication
December 23, 2022 - Novo Nordisk announced the FDA approval of Wegovy (semaglutide), for chronic weight management in pediatric patients aged 12 years and older with an initial body mass index (BMI) at the 95th percentile or greater for age and sex (obesity).
Top